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 Where can urodynamic testing help assess male 
lower urinary tract symptoms? 
Abstract  
Urodynamic studies assess the function of the bladder and bladder outlet and are often useful in the 
assessment and diagnosis of patients presenting with lower urinary tract symptoms (LUTS). The 
evidence regarding the value and risks of invasive urodynamics remains insufficient. However, men 
with LUTS who are assessed by invasive urodynamics are more likely to have their management 
changed and less likely to undergo surgery. This review discusses the role of urodynamic diagnosis 
and application in the diagnosis and treatment of male LUTS. 
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Lower urinary tract symptoms (LUTS) comprise storage symptoms, voiding symptoms and post-
voiding symptoms. [1] LUTS are prevalent and bothersome in men of all ages. [2,3]  Determining the 
underlying mechanism is important in choosing the optimal management. [4]  Invasive urodynamic 
tests (filling cystometry and pressure flow studies) are used to investigate men with. LUTS to 
determine a definitive objective explanation. A Committee of the International Consultation on 
Incontinence (ICI) advised that the investigation should be performed before surgical intervention. [5]  
However, urologists have been undecided on whether urodynamic studies (UDS) bring essential 
information, or whether a sufficient assessment can be achieved by clinical evaluation alone.  
This review covers recent research on the role of urodynamic diagnosis and application in the 
diagnosis and treatment of male LUTS. Several tests, including non-invasive free flow rate testing, 
penile cuff test (PCT), external condom catheter and doppler ultasound and near-infrared 
spectroscopy can be described as urodynamic tests. Attempts to find non invasive alternatives have 
not yet revealed an adequate approach. Therefore, invasive urodynamics remains the key indicative 
test in the care path way for male LUTS.[6]    
 
Urodynamic testing  
The term ‘‘Urodynamics’’ was defined as the assessment of the function and dysfunction of the 
urinary tract by any appropriate method. [7,8]   UDS allows direct assessment of LUT function by the 
measurement of relevant physiological parameters during filling cystometry and pressure-flow study 
(PFS). It  is carried out in an assessment pathway that also can include symptom score, bladder diary 
assessment, uroflowmetry and post void residual urine (PVR) evaluation, as set out by the 
International Continence Society (ICS). [9] It is always driven by the LUTS reported by the patient, 
specifically whether any particular symptom remains bothersome despite conservative or medication 
therapy.   
Invasive urodynamics (Figure 1) involves the placement of intravesical and rectal catheters. Bladder 
pressure (Pves) is normally recorded via a fine, fluid-filled catheter passed into the bladder via the 
urethra with the distal end connected to an external pressure transducer. The continuous 
subtraction of the pressures in the rectal line (Pabd) from those in the vesical line gives the ‘detrusor 
pressure’ (Pdet), and estimate of bladder contraction. The bladder is filled at a steady rate with body 
temperature isotonic saline (filling cystometry; CMG) (Figures 1 and 2), until the patient reports a 
strong desire to void or experiences severe urgency or severe incontinence. Following ‘permission to 
void’ uroflowmetry is performed while still recording pressures (pressure flow study; PFS) (Figures 1 
and 3).  
 
Rationale of testing and interpretetion of findings  
The measurements are performed with the aim of answering the following two questions; 
1- In the storage phase; Can the bladder be filled to normal capacity without leakage or 
significant pressure rise, due to either an overactive detrusor or low compliance?  
2- In the voiding phase; Can the patient empty his bladder completely, with a normal flow rate 
and voiding pressure, without straining? 
Filling is ideally started with an empty bladder. Normally detrusor pressure should remain near zero 
during the entire filling cycle until voluntary voiding is initiated. Involuntary bladder contractions can 
occur with filling and are seen as a rise in Pves in the absence of a rise in Pabd. This phenomenon is 
known as detrusor overactivity (DO) (Figure 2). DO may be accompanied by a feeling of urgency or 
even loss of urine (DO incontinence). Steady rise in pressure with filling indicates impaired 
compliance, which is quantified by the relationship between change in bladder volume and detrusor 
pressure (∆Volume/∆ p det); a value of less than 20 mL/cm H2O implies a poorly accommodating 
bladder. [10]   
 
The most important values from the PFS (Figure 3) are the maximum flow rate (Qmax) and the Pdet at 
that moment (termed the PdetQmax). High pressure associated with a slow flow rate implies bladder 
outflow obstruction (BOO); if slow flow is associated with low pressure, it signifies detrusor 
underactivity (DUA). The BOO index (BOOI) gives a quantitative assessment of BOO and is calculated 
using the formula PdetQmax-2Qmax. If the BOOI is greater than 40, the patient has BOO; if less than 20, 
no obstruction exists; values between 20 and 40 are described as equivocal. [11] The bladder 
contractility index (BCI) is another parameter, calculated by the formula PdetQmax- 5Q. [12] A BCI of 
greater than 100 is normal; and less than 100 indicates DUA. 
 
Clinical applications of UDS for male lower urinary tract symptoms 
The PFS measures the relationship between detrusor pressure and flow rate during voiding. While a 
low flow rate alone may be more likely to be associated with BOO, it is not always the case. Hence, 
the principal purpose of the PFS is to differentiate BOO from DUA. Likewise, patients with relatively 
normal flow rate sometimes turn out to have quite elevated detrusor pressures suggestive of 
obstruction, a diagnosis which can only be made during pressure flow analysis. [13,14] The importance 
of recognising BOO and/ or DUA, is in deciding treatment. Specifically, it supports whether to 
recommend BOO relieving surgery, such as transurethral resection of the prostate (TURP). DUA is 
present in 9–48% of men undergoing urodynamic evaluation for non-neurogenic LUTS. [15]  If BOO is 
truly present, successful surgery should improve voiding, but not if DUA is a signifcant factor. [16,17] 
Lower urinary tract symptoms may reflect many potential underlying pathophysiological 
mechanisms. Young men with. LUTS have a different prevalence of underlying etiologies than older 
men. About one-third of men older than 55 years with LUTS had benign prostatic obstruction, but 
younger men were more likely to have poor relaxation of the urethral sphincter. [18]   
The ICS defines overactive bladder (OAB) syndrome as urgency, with or without urgency 
incontinence (UI), usually with increased daytime frequency and nocturia. This symptom-based 
definition is distinct from detrusor overactivity, which is the urodynamic observation of bladder 
contractions during filling, which may be spontaneous or provoked. The correspondence of OAB 
symptoms and urodynamic DO is fairly reasonable in men- more so than in women. [19] However, the 
symptoms of overactive bladder can be mistakenly attributed to benign prostatic enlargement (BPE). 
The logic behind this is unclear, since obstruction impedes urine flow, it does not influence detrusor 
contraction during storage. The role of UDS in the initial evaluation of men with OAB is unclear, since 
it has not translated into observations relevant to therapy choice or prediction of outcome. 
Nonetheless, many physicians perform UDS after the failure of conservative medical management. 
It is remains unknown whether preoperative DO is a significant predictor of surgical outcomes in 
patients with male BOO. [20] There are few available studies exploring the significance of preoperative 
DO in transurethral surgery, and some of them have controversial results. [21,22] Although men with 
urgency urinary incontinence (“OAB wet”) usually have urodynamic DO incontinence, this is 
sometimes not the case.  
 
Diagnostic value of urodynamic bladder outlet obstruction to select patients for surgery of the 
prostate 
A meta-analysis done by Kim and colleagues in 2017 showed a significant association between 
urodynamic BOO and better improvements in all treatment outcome parameters. [23] 19 articles met 
the eligibility criteria, including a total of 2321 patients, but none of the studies employed a 
prospective design. The parameter to specify urodynamic BOO varied between studies, though 
generally it was defined as BOOI > 40. The review reported that BOO positive patients have better 
surgical outcomes in all parameters (symptom score, quality of life, Qmax and PVR) compared to BOO 
negative patients. While BOO negative patients sometimes saw symptomatic improvement after 
surgery, it was less than that in the BOO positive group, and adverse effects compound the 
complexity of reporting LUTS improvement.  
The Cochrane Database of Systematic Reviews searched for all randomised or quasi-randomised 
controlled trials on the management of voiding dysfunction in which men with symptoms were 
randomly assigned to invasive urodynamic testing in at least one arm of the study. [24] Only two trials 
met the inclusion criteria[25,26]  and analysis was only possible for 339 men in one trial. No difference 
was seen in Qmax or IPSS before and after surgery for LUTS in the two groups who underwent UDS or 
did not. However, the test was influential for therapy choice.  
The UPSTREAM study (Urodynamics for Prostate Surgery Trial: Randomised Evaluation of Assessment 
Methods) is a prospective randomised controlled trial in 820 men who have bothersome difficulty 
passing urine and who are considering having surgery for the symptoms. [27] Patients were 
randomized to two arms; the first undergoing clinical evaluation and flow-rate testing, the other 
additionally undergoing Urodynamic testing. The trial will determine whether urodynamics reduces 
surgery rates while achieving similar symptom outcome, and will report in 2019. The first qualitative 
results have been published, and revealed that the patients value the additional information that 
urodynamic testing brings. [28]  
 
Implications of preoperative urodynamic detrusor underactivity on prostate surgery 
The effect of DUA on transurethral surgery outcomes was evaluated in 10 non-randomised studies 
covering 1113 patients. [29] The parameter used to identify DUA was BCI < 100. DUA was significantly 
associated with worse outcomes for symptoms and Qmax. However, since some improvement was 
sometimes seen, DUA is not an absolute contraindication for surgery, provide the patient is fully 
counselled. 
 
Implications of storage dysfunction for surgery to relieve BOO 
Seki and colleagues evaluated whether urodynamic findings have any predictive value regarding the 
outcome after TURP. A retrospective review was done for 1,397 men. Multivariate analysis suggested 
that the presence of DO was an independent determinant against symptom improvement. [30]  The 
statistical analysis revealed that patients with greater initial storage problems attained less 
improvement after prostatectomy.Persistent DO can be noted in about 30% and 50% of the patients 
after prostatectomy. [31,32] The emergence of de novo DO is unusual following prostatectomy, so any 
post-operative DO is likely to represent persistence of DO, as opposed to new onset.  
 
Evaluation of medical treatment of LUTS by urodynamic studies  
Most recommendations place UDS after conclusion of conservative therapy, but if used at an earlier 
stage the information does provide some insight into mechanisms by which medications might bring 
clinical response. A systematic review and meta-analysis of studies evaluating alpha adrenergic 
antagonists (alpha blockers) for urodynamic outcomes in patients with LUTS/BPE were performed by 
Fusco et al. [33] Alpha blockers improved BOOI mainly by reducing PdetQmax, particularly where BOO 
was present at baseline. Meta-regression analysis demonstrated a significant positive association 
between the percentage of patients with obstruction at baseline and the improvement in BOOI after 
alpha blocker treatment. As a consequence, patients with obstruction can be regarded as the 
subpopulation that could benefit the most from alpha blocker therapy, as opposed to those merely 
with voiding LUTS. Nonetheless, PFS is not routinely performed in clinical practice to identify the 
subgroup of men with BOO among those presenting with voiding LUTS. This is simply because the 
easily-reversible nature of drug therapy, and relatively low risk of adverse effect, makes the cost and 
adverse effects of UDS difficult to justify. According to the EAU guidelines, free uroflowmetry may be 
performed in the initial assessment of male LUTS. However, a threshold free Qmax value of 15 ml/s 
has a positive predictive value of only 67% for BPO, which means that approximately one third of 
men treated with alpha blockers at this level do not really have obstruction. [34] Most studies 
evaluating alpha blocker therapy for LUTS/BPE consider free Qmax as the only urodynamic measure of 
treatment effect. However, treatment induced improvements in this parameter are generally loosely 
related, [35] and the actual urodynamic response may be a relevant decrease in PdetQmax. [33]  
More than 50% of maleLUTS patients have complaints of storage symptoms requiring anticholinergic 
therapy. [36] Initial combination treatment employing both alpha blockers and anticholinergics could 
improve response and ameliorate adverse events in male patients with voiding and OAB symptoms. 
[37,38,39]  Only a few studies have used urodynamic measurements to monitor clinical changes with 
anticholinergic treatment in men with LUTS. [40,41] PdetQmax and Qmax were assessed by combination of 
alpha blocker plus anticholinergic versus placebo, and was found to be non-inferior to placebo. 
Hence, the clinical value of UDS on combination therapy choice is still doubtful. 
 
Risks of invasive urodynamic tests  
Urodynamic studies are generally well tolerated and perceived valuable by patients due to the 
additional insight brought into the symptoms. [42]  However, men may find testing to be an 
uncomfortable or embarrassing experience. The main risks of urodynamic testing are those 
associated with the process of urethral catheterisation, such as dysuria (painful urination) and 
urinary tract infection (UTI). The rate of bacteriuria reported after UDS ranges from 4% to 9%.[43,44]  
 
Practical management of male LUTS   
Diagnostic pathways and thresholds of testing to evaluate male LUTS generally include evaluations to 
exclude a serious underlying health factor, symptom score, bladder diary, urinalysis, freeflow rate 
testing with PVR measurement. Additional tests may be undertaken individually. The flow diagram 
(Figure 4) illustrates an approach to the diagnostic pathway for male LUTS, and the potential 
contribution of UDS. 
 
                            
Conclusion  
Urodynamic studies provide an objective evaluation of the patient’s presenting LUTS, which often 
provide an uncertain relationship in predicting the underlying UDS findings. Distinguishing between 
voiding LUTS due to BOO and or DUA is important, as this issue may influence management decisions 
specifically related to surgery for BOO. Low-level evidence suggests that making this distinction is 
important, as clinical out comes may be affected. 
Limited evidence suggests that UDS helps to predict which men with bothersome LUTS will benefit 
from surgery and medical treatments. Invasive urodynamics is generally well tolerated and leads to 
far fewer complications than avoidable surgery, and very few serious long-lasting issues. Publication 
of the UPSTREAM trial data will help identify the best approach to the diagnostic pathway. Until that 
is clear, we recommend an inclusive approach to using invasive urodynamics to complete the full 
assessment of those men who have failed conservative management of bothersome LUTS. 
 
Abbreviations: 
BOO (bladder outlet obstruction), BOOI (Bladder Outlet Obstruction Index), BPO (benign prostatic 
obstruction), BPE (Bening Prostate enlargement), .LUTS (lower urinary tract symptoms),), PVR 
(postvoid residual), Qmax (maximum flow rate), Urodynamic studies (UDS), Detrusor Overactivity 
(DO), Pressure flow studies(PFSs), Committee of the International Consultation on Incontinence (ICI), 
detrusor underactivity (DUA) 
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Figure 1; An example of a full urodynamic trace, plotting volume instilled (orange), Pabd (red), Pves 
(blue), Pdet (green) and flow (black). The filling cytometry is before permission to void (PTV), the 
pressure flow study is after. Coughs are denoted by the letter c, and first desire to void (FDV) is also 
annotated. The detrusor is stable (no change in Pdet during filling), and the bladder shows a clear 
contraction for voiding (rise in Pdet for voiding), though flow is rather slow (8 ml/s) and prolonged 
(more than a minute). PdetQmax was 51, so the bladder outlet obstruction index was 35 (i.e. 
equivocal) and the bladder contractity index was 91 (underactive) 
 
Figure 2; Detrusor overactivity (DO) during filling cystometry. On the left, a bladder contraction (rise 
in pressure in Pdet, caused by rise in Pves) is seen. On the right, a high amplitude DO contraction is 
seen, initially without leakage. At this point, the patient is preventing leakage by contracting his 
pelvic floor (which can be seen because the rectal catheter crosses the pelvic floor, and so there is a 
rise in the pressure plotted in the red line). After a while, the pelvic floor gets tired, so incontinence 
happens- this is not voiding, as permission to void has not been given. 
 
Figure 3; Pressure flow studies for two different men. On the left, the flow rate is slow, with a Qmax 
of only 5 ml/s. Detrusor pressure at the time of Qmax was 102 cmH2O, so the BOOI was 92 
(obstructed) and the BCI was 127 (normal contractility). On the right, the Qmax is also only 5, but the 
synchronous detrusor pressure was 24, so BOOI was 14 (not obstructed) and the BCI was 49 
(substantially underactive) 
Figure 4- Assessment of male LUTs flow diagram. PE: physical examination; ABs: alpha blockers; UDS: 
Urodynamic study; Q: Questionaires; LUTS: Lower urinary tract symptoms. 
 
 
 
 
  
 
 
